A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

2025-522076-85-00 · tracked via the Priya Life Science EU tracker

Sponsor

AstraZeneca AB

Sponsor type

Pharmaceutical company

Therapeutic area

Immune System Diseases

Decision date

22/04/2026

Enrollment target

Sites

Hungary, Spain, Bulgaria, Germany, Poland

Condition studied

Rheumatoid arthritis

Investigational medicinal product(s)

AZD1163 PlaceboAZD1163

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

Endpoint detail

Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12 - Percentage of Participants Achieving ACR50 at Week 12 - Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12 - Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12, AZD1163 concentrations in serum., ADA (incidence, prevalence, and titres)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522076-85-00 on CTIS ↗ ← All trials in the EU